Arthneeti

Lyka Labs Q2 FY27 Share Price & Earnings Call Analysis

₹75.57+0.67% today
Market cap
₹273 Cr
ROE
-10.18%
Price to sales
1.98
Debt to equity
0.53
52W high / low
₹94.7 / ₹45.0
Sales growth (5Y)
8.29%
EBITDA margin
-2.03%
Net profit margin
-8.12%
Promoter holding
58.45%
Sales (last year)
₹138 Cr

Incorporated in 1976, Lyka Labs Ltd is in the development, manufacture and marketing of quality finished dosages[1]

Potential multibaggers · Q2 FY27

Potential multibaggers in Pharmaceuticals & Biotechnology
on management's own guidance

  1. Strong growth
    2
  2. Strong growth
    1
  3. Strong growth
    3
See all potential multibaggersWhere does Lyka Labs Ltd rank?

Portfolio builder

Build your portfolio
from the top-ranked stocks

  1. 1. Pick 3–15 stocks
  2. 2. Choose large, mid or small cap and your sectors
  3. 3. Get a portfolio built from the rankings
Build my portfolio

Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.

Peers

Pharmaceuticals & Biotechnology companies ranked on guidance

#CompanyRevenue guidedMargin guidedMarket capP/E
140%+Up 2%+₹480 Cr19.1
240%+Up 0–2%₹212 Cr16.1
340%+Flat₹17,925 Cr—
440%+Flat₹5,223 Cr39.1
540%+Flat₹4,268 Cr—
640%+Flat₹40 Cr—

Sign up free to see every company in the sector ranking and track Lyka Labs Ltd.

Pro shows every company guiding 40%+ revenue growth →Full Pharmaceuticals & Biotechnology ranking

Financials of Lyka Labs Ltd

Quarterly Results, Profit & Loss, Balance Sheet, Cash Flows, and Ratios are shown below as separate sections.

Shareholder Pattern

Lyka Labs Ltd

Shareholding breakup across reporting periods.

Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026Sep 2026
Promoters +54.81%54.81%58.11%58.11%58.11%58.16%58.16%58.16%58.16%58.16%58.45%58.45%
FIIs +0.17%0.17%0.15%0.15%0.15%0.24%0.16%0.17%0.17%0.29%0.17%0.15%
DIIs +0.62%0.81%0.75%0.66%0.66%0.66%0.66%0.66%0.66%0.66%0.66%0.66%
Public +44.41%44.21%40.99%41.08%41.07%40.93%41.02%40.99%40.99%40.89%40.73%40.73%
No. of Shareholders26,42225,71725,71628,94329,09928,47228,18927,74327,15526,72729,36925,885

Financials of Lyka Labs Ltd

Quarterly Results

Quarter-by-quarter operating performance

Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026Sep 2026
Sales +27.9932.5627.7730.1141.1633.8033.4333.0336.6630.7328.0342.3144.20
Expenses +23.8225.6925.7526.4036.2128.6129.3529.3539.2029.0834.4837.7640.68
Operating Profit4.176.872.023.714.955.194.083.68-2.541.65-6.454.553.52
OPM %14.90%21.10%7.27%12.32%12.03%15.36%12.20%11.14%-6.93%5.37%-23.01%10.75%7.96%
Other Income +-0.180.540.320.560.030.830.820.631.091.160.610.420.62
Interest1.191.281.070.650.540.610.470.850.790.820.701.011.02
Depreciation3.592.842.901.761.761.831.422.112.152.152.042.012.05
Profit before tax-0.793.29-1.631.862.683.583.011.35-4.39-0.16-8.581.951.07
Tax %-22.78%38.60%28.22%30.65%28.36%24.30%32.89%26.67%-26.65%-6.25%-6.06%-5.13%-18.69%
Net Profit +-0.491.78-2.091.291.912.702.030.99-3.22-0.15-8.072.051.27
EPS in Rs-0.150.54-0.630.400.590.760.500.26-0.940.00-2.130.570.36

Financials of Lyka Labs Ltd

Profit & Loss

Annual income statement trend

Jun 2015Mar 2016 9mMar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026TTM
Sales +1661301106071618619493111138128145
Expenses +1391108763736567937695121132142
Operating Profit282023-4-2-420101171618-33
OPM %17%16%21%-6%-2.7%-6%23%52%18%14%13%-2.7%2.2%
Other Income +48-241-300-4-41243
Interest241519107202620125234
Depreciation1191011788171413788
Profit before tax-34-8-20-15-62-1459-13-111-12-6
Tax %31%-5%-19%-5%-59%1%-29%35%-0%182%29%-11%
Net Profit +-54-7-19-6-63-1038-13-38-10-5
EPS in Rs-2.291.67-2.51-6.14-1.97-21.10-4.0313.59-4.30-0.752.24-2.81-1.20
Dividend Payout %0%0%0%0%0%0%0%0%0%0%0%0%

Financials of Lyka Labs Ltd

Balance Sheet

Capital structure and asset base

Jun 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026Sep 2026
Equity Capital22222228282929293133363636
Reserves2022162115-43-54-151535695760
Borrowings +137121126113961411631307559394944
Other Liabilities +100778867767352423130323342
Total Liabilities279242252229216200190186152157176175182
Fixed Assets +12210413311610810598946858858789
CWIP27302428312826181623123
Investments0000000000000
Other Assets +1301079485776866746776908691
Total Assets279242252229216200190186152157176175182

Financials of Lyka Labs Ltd

Cash Flows

Operating, investing and financing cash movement

Jun 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Cash from Operating Activity +271231112759799225
Cash from Investing Activity +3717-13-3-4-0-0-67-9-12-9
Cash from Financing Activity +-60-30-19-10-233-12-63-22254
Net Cash Flow4-1-0-3-19-310-5-6-50
Free Cash Flow552818723487215-7-10-6
CFO/EBITDA Share of operating profit converting into cash: CFO (before tax) / Operating Profit97%60%143%-318%-1,462%-131%49%79%52%21%28%-159%

Financials of Lyka Labs Ltd

Ratios

Working capital efficiency and return ratios

Jun 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Debtor Days12412197125754837357989114100
Inventory Days7756901396569415668788299
Days Payable22021826630121619214196919898122
Cash Conversion Cycle-18-41-79-37-75-76-63-555689776
Working Capital Days-220-242-357-735-265-242-118-121-0235123
ROCE %10%7%9%-8%-5%-6%10%61%5%4%10%-6%

Continue your research

What Lyka Labs Ltd's management said in earlier quarters

Others in Pharmaceuticals & Biotechnology this season

  • Anthem Bioscienc (Q2 FY27)

    Q2FY27 Consolidated Revenue from Operations: ₹5,940 Mn, up 7.9% YoY from ₹5,505 Mn in Q2FY26 (Page 4). Key investor presentation takeaways from Anthem Bioscienc

  • Neuland Laboratories (Q2 FY27)

    Q2FY27 Total Income (revenue) was ₹457.2 crore, down 11.4% year-on-year (YoY) from Q2FY26. Key investor presentation takeaways from Neuland Laboratories Ltd's Q

  • Hikal (Q2 FY27)

    Consolidated Revenue Q2FY27:** ₹434 crores, up 36% YoY from ₹319 crores in Q2FY26 (Page 9) . Key investor presentation takeaways from Hikal Ltd's Q2 FY27 invest

  • Kopran (Q2 FY27)

    9,335 lakhs (~79% increase) . Key investor presentation takeaways from Kopran Ltd's Q2 FY27 investor presentation — and how it ranks against sector peers.

Compare:vs Sun Pharmaceutical Industriesvs Divis Laboratoriesvs Torrent Pharmaceuticals